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Mycophenolate mofetil (MMF) and mycophenolate sodium (MPS) are an ester and a salt of mycophenolic 
acid. They have different kinetic in vivo characteristics due to differences in molecular structures, 
physicochemical properties and formulations administered. In this study, dissolution profiles of reference 
products were tested in different media to evaluate the effect of pH, kinetic dissolution and the best 
statistical model that can be used to predict the release of both drugs. The drug release was determined by 
using a validated ultraviolet spectrophotometry method, λ 250 nm. The method showed to be selective, 
linear, precise and accurate for MMF in 0.1 M HCl and MPS in sodium phosphate buffer pH 6.8. 
Dissolution kinetics models of zero order, first order, Higuchi, Hixson-Crowell and Weibull were applied 
to data in order to select the best fit by linear regression. The regression parameters were estimated and 
the models were evaluated with the results of residuals and coefficient of determination. The residuals 
obtained from dissolution kinetics models were random, uncorrelated, and normally distributed with 
constant variance. The R2 values (74.7% for MMF and 95.8% for MPS) demonstrated good ability of 
the Weibull regression to explain the variability and to predict the drugs’ release.
Uniterms: Mycophenolate sodium. Mycophenolate mofetil. Dissolution profiles. Weibull kinetics.
Micofenolato de mofetila (MMF) e micofenolato sódico (MPS) são, respectivamente, éster e sal sódico 
do ácido micofenólico. Os fármacos possuem características farmacocinéticas distintas em função das 
diferenças na estrutura molecular, nas propriedades físico-químicas e nas formulações administradas. 
Neste trabalho, os perfis de dissolução dos medicamentos referências foram testados em diferentes 
meios de dissolução com o objetivo de avaliar o efeito da variação de pH, a cinética de dissolução e o 
modelo estatístico mais adequado para prever a dissolução dos fármacos. A liberação dos fármacos foi 
determinada com método validado por espectroscopia no ultravioleta, λ 250 nm. O método mostrou-se 
seletivo, linear, preciso e exato para dissolução de MMF em 0,1 M HCl e MPS em tampão fosfato pH 
6,8. Os modelos cinéticos de dissolução de ordem zero, primeira ordem, Higuchi, Hixson-Crowell e 
Weibull foram aplicados com o objetivo de selecionar aquele com o melhor ajuste por regressão linear. 
Os parâmetros de regressão foram estimados e os ajustes dos modelos foram verificados pelos resíduos 
e coeficientes de determinação. Os resíduos obtidos foram aleatórios, independentes, apresentaram 
variância constante e seguiram a distribuição normal. Os valores de R2 (74,7% para MMF e 95,8% para 
MPS) indicaram bom ajuste da regressão de Weibull para explicar a variabilidade e estimar a liberação 
dos fármacos.
Unitermos: Micofenolato sódico. Micofenolato de mofetila. Perfil de dissolução. Cinética de Weibull.
INTRODUCTION
Mycophenolic acid (MPA), commonly used in the 
immunosuppressive therapy of post-transplant patients, 
is a specific, non-competitive and reversible inhibitor of 
inosine monophosphate dehydrogenase (Noronha et al., 
2005; Sánchez-Fructuoso, 2005; Staatz, Tett, 2007). It 
is administered as a pro-drug, the ester mycophenolate 
mofetil (MMF), or its salt, mycophenolate sodium (MPS) 
(Figure 1).
Following oral administration, MMF undergoes 
rapid and extensive absorption and complete pre-systemic 
A. L. O. Costa, P. C. R. Enéas, T. A. Miranda, S. A. Mingoti, C. D. V. Soares, G. A. Pianetti312
metabolism to MPA. The active metabolite reaches 
maximum plasma concentration after 1 h and a secondary 
increase in plasma is observed at approximately 6-12 
h post dose (Staatz, Tett, 2007; Lee et al., 1990; Jeong, 
Kaplan, 2007).
Enteric-coated mycophenolate sodium (EC-MPS) 
was developed to reduce the incidence and severity of 
gastric side effects of mycophenolate mofetil immediate 
release tablets (MMF-IR) used in immunosuppressive 
therapy. The goal of this formulation development was 
delaying release and absorption of MPA to reduce the 
incidence of gastrointestinal effects (Arns, 2007; Budde et 
al., 2004; Sábada et al., 2005). After oral administration of 
EC-MPS the absolute bioavailability is greater than 71% 
and peak plasma concentration is reached within 1.5 to 2 h 
(Sánchez-Fructuoso, 2005; Zolezzi, 2005).
Several analytical methods for MPA have been 
established to support pharmacokinetics studies of EC-
MPS compared with MMF-IR in human and animal models 
(Tsina et al., 1996; Barkosi, 2005; Wiwattanawongsa, 
2001). The drugs demonstrated similar efficacy and safety 
profile, indicating that patients receiving MMF-IR as 
maintenance therapy can be safely interchanged to EC-
MPS. However, there is no consensus on reducing the 
adverse effects (Sánchez-Fructuoso, 2005; Arns, 2007; 
Budde et al., 2004; Sábada et al., 2005; Zolezzi, 2005).
Despite similar safety and efficacy, the tablets may 
present different drug releases after oral administration. 
The objectives of this work were evaluated dissolution 
profiles of MMF-IR and EC-MPS in different media 
to determine the pH effect on drug release and applied 
statistical models to describe the dissolution kinetics.
MATERIAL AND METHODS
Reagents and chemicals
MPA from Sigma-Aldrich® (St. Louis, MO, USA, 
batch 097K4005) and MMF reference standard from 
European Pharmacopoeia, batch 2.0, were obtained. The 
reference tablets CellCept® 500 mg (MMF-IR, Roche) 
and Myfortic® 360 mg (EC-MPS, Novartis) were used. 
The analytical reagents concentrated hydrochloric 
acid, methanol, sodium monobasic phosphate and 
sodium tribasic phosphate were purchased (J.T. Baker®, 
Phillipsburg, NJ, USA). High purity water was used 
(Milli-Q, Millipore®, Bedford, MA, USA).
Instrumentation and analytical conditions
The dissolution profiles were performed in a 
dissolution system (Erweka® DT80) in accordance to 
specifications of The United States Pharmacopeia (USP 
34, 2011). The drug release percentage was determined in 
a UV-Vis spectrophotometer (HP8453, Agilent, Palo Alto, 
CA, USA) at λ 250 nm, in adequate diluents.
Dissolution profiles
Immediate release profile of MMF was carried 
out using six units in each medium: 0.1 M HCl, 0.01 M 
HCl and 0.1 M sodium phosphate buffer (PBS) pH 3.0 
maintained at 37±0.5 °C. Paddle apparatus were used at 
50 rpm and dissolution points were defined at 5, 10, 15, 
30, 45 and 60 min. The samples were filtered through a 
0.45 µm membrane and exactly diluted to approximately 
25 µg/mL. The amount of MMF dissolved was determined 
against MMF standard solution in dissolution medium at 
same concentration.
Dissolution profiles for EC-MPS tablets were 
obtained according to USP general method <711> for 
dissolution of enteric-coated tablets. The dissolution 
started with 750 mL 0.1 M HCl at 37±0.5 °C and paddle 
apparatus at 50 rpm. After 120 min, an aliquot was 
collected and 250 mL of 0.20 M sodium phosphate buffer 
tribasic, 37±0.5 °C, were added. The pH of each vessel was 
rapidly adjusted to 6.8±0.05. The amount of MPS dissolved 
FIGURE 1 – Chemical structures of (a) mycophenolic acid, (b) 
mycophenolate mofetil and (c) mycophenolate sodium.
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was determined after 10, 20, 30, 45, 60, 90 e 120 min 
in buffer medium. A stock solution of MPA standard 
was prepared in methanol at 450 μg/mL and diluted in 
dissolution media to final concentration of 18 μg/mL. 
The same procedure was performed to obtain dissolution 
profiles at adjusted pH values of 6.0±0.05 and 5.5±0.05. 
Statistical comparison was performed by Duncan 
test at 95% of confidence for the selection of an ideal 
medium and, dissolution test specifications were proposed 
for each drug. The difference of average drug release at 
each time point was considered significantly if it was 
larger than the critical value. Similarity factor (f2) was 
also determined to compare the curves of dissolution. 
In Equation 1 for f2 factor, n is the number of dissolution 
points, Rt and Tt are the reference and test dissolution 
values at time t. Values of f2 between 50 and 100 ensure 
the sameness of two dissolution profiles (USA, 1997).
 Eq. 1
Dissolution kinetics
Mathematical models are often used to describe 
dissolution profiles and to compare drug release by 
dependent method. The evaluation of dissolution kinetics 
allows knowing the rate of the process, the maximum 
concentration dissolved and when significant, changes 
occur (Patel et al., 2008; Raslan, Maswadeh, 2006; 
Demirturk, Oner, 2005; Serra, Storpirtis, 2007).
The release kinetics of MMF-IR tablets in 0.1 M 
HCl and EC-MPS in PBS pH 6.8 were analyzed by linear 
regression using different mathematical models (see Table 
I). The general function of a simple linear regression is 
described by Equation 2, where β0 is the intercept, β1 is 
the slope and ε the random error (residual) with zero mean 
and variance σ2.
 f(xi) = β0 + β1 xi + εi  Eq. 2
Regression parameters (β0 and β1) were estimated by 
least squares method and the best fit model was selected 
for each drug based on the results of the coefficient of 
determination (R2) and residual analyses. The observations 
at 5, 10, 15 and 30 min were used for MMF-IR. The 
kinetics studied for EC-MPS were assessed in the time 
interval 10-45 min in the buffered stage.
Pharmaceutical dosage forms that follow zero 
order kinetics, release the same amount of drug per unit 
of time. In the first order kinetics, the plot of dissolution 
time versus natural logarithm of the percentage dissolved 
drug was evaluated. Drug release occurs proportionally 
to the drug amount remaining inside the dosage form, so 
that the amount of drug released per unit time decreases 
(Manadas et al., 2002).
Higuchi developed several theoretical models to 
study the release of soluble and poorly soluble drugs 
incorporated in solid and semi-solid matrices. The 
simplified Higuchi model is based on Fick’s law of 
diffusion and the square root of time is described versus 
drug release (Manadas et al., 2002). The equation of the 
Hixson-Crowell model considers the principle that the area 
of a particle is proportional to the cube root of its volume. 
This model assumes that the release rate is limited by the 
dissolution of the particles of the drug and not by diffusion 
in the matrix tablet.
The general empirical equation described by Weibull 
(Equation 3) was applied to the drug release processes 
and provides satisfactory results for almost all types of 
dissolution curves.
 log[–ln(1 – m)] = βlog(t – Ti) – log  Eq. 3
In Weibull model, the statistical parameter α defines 
the time scale of the process estimated from X value (t=1), 
Ti represents the time interval before dissolution starts (Ti=0) 
and β is the shape parameter that characterizes the curve 
as exponential (β=1), sigmoid (β>1) or parabolic (β<1). 
TABLE I - Regression models applied to dissolution profiles of MMF-IR and EC-MPS tablets
Model Equation β0 β1
Zero order Qt = Q0 + k0t Q0 k0
First order ln Qt = ln Q0 + k1t ln Q0 k1
Higuchi Qt = Q0 + kHt1/2 Q0 kH
Hixson-Crowell Q01/3 – Qt1/3 = kwt Q0 1/3 kW
Weibull log[–ln(1 – m)] = βlog(t – Ti) – log  − log α β
Qt: amount of drug released in time t; Q0: initial amount of drug in dissolution media; k0 , k1 , kH , kW : release rate constants; 
m: accumulated fraction of the drug; α: scale parameter; β: shape parameter; Ti: location parameter.
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The Weibull linear relationship was obtained by log-log 
plot of time versus -ln (1-m), where m is the cumulative 
fraction of drug dissolved over a time t (Manadas et al., 
2002; Yukse et al., 2000).
Method validation
Spectrophotometric method was validated regarding 
merit figures specificity, linearity, accuracy, precision, 
detection (LOD) and quantitation limits (LOQ) for 
MMF-IR in 0.1 M HCl and, for EC-MPS in PBS pH 
6.8, according to ICH guidelines (ICH, 2005). EC-MPS 
determination was expressed in the equivalent amount of 
MPA.
Placebo enriched by standard solutions was used 
to evaluate selectivity over the range 200-400 nm. 
MMF-IR placebo formulation contained microcrystalline 
cellulose, croscarmellose sodium, magnesium stearate, 
Povidone K-90, Hypromellose, titanium dioxide, indigo 
carmine and yellow iron oxide. EC-MPS placebo was 
composed by corn starch, Povidone K-90, Crospovidone, 
lactose, colloidal silicon dioxide, magnesium stearate, 
Hypromellose, titanium dioxide, indigotine, yellow iron 
oxide and red iron oxide.
Linearity was evaluated by thirty determinations 
across the range 5.0-50.0 μg/mL for MMF and by twenty 
four determinations across the range 6.0-34.0 μg/mL for 
MPA. The results were analyzed by visual inspection and 
a regression model estimated by the least squares method. 
Detection and quantitation limits were estimated based on 
the standard deviation of the intercept (sa) and the slope 
(b) of the respective analytical curve were used following 
Equations 4 and 5.
 LOD = 3.3 sa / b  Eq. 4
 LOQ = 10 sa / b  Eq. 5
Precision was investigated in the tablets by 
repeatability (intra-day) and intermediate precision 
(inter-day) using six determinations in three different days. 
Final test concentrations were 25 µg/mL for MMF and 
18 µg/mL for MPA. Intra-day precision was reported as 
relative standard deviation (RSD) and inter-day precision 
was evaluated by comparison of the means in different 
days, by Anova (α=0.05).
In order to evaluate accuracy, three placebo samples 
were added of different standard concentrations of 
MMF (17.5, 25.0, 32.5 µg/mL) and of MPA (12.6, 18.0, 
23.4 µg/mL). Recovery was expressed by the ratio of 
experimental to nominal drug percentage concentrations.
RESULTS
Dissolution profiles
The MMF-IR dissolution profiles shown in Figure 2a 
were statistically different at all sampling times (p<0.05). 
It was observed that the amount of MMF released in 
PBS pH 3.0 was significantly different to that released in 
0.1 M HCl (p<0.05) at all points. The dissolution profile 
in 0.01 M HCl was not significantly different to that 
in PBS pH 3.0 at initial points (p>0.05). However, the 
dissolution curves in media 0.01 M HCl and 0.1 M HCl 
yield superposed points, starting at 30 min, in the plateau 
region (see Table II).
The similarity factor was applied to compare the 
dissolution profile over 0-30 min (critical interval of 
dissolution). In a similar drug dissolution was observed the 
curves in 0.1 M HCl vs. 0.01 M HCl (f2 = 53.15), as well as 
for those in 0.01 M HCl vs. PBS pH 3.0 media (f2 = 70.37). 
However, the curves were considered statistically different 
FIGURE 2 - Cumulative amount release for (a) MMF-IR in 0.1 
M HCl, 0.01 M HCl and PBS pH 3.0 and for (b) EC-MPS in 
PBS pH 5.5, 6.0 and 6.8 at 37±0.5 °C, paddles, 50 rpm, using 
UV method, λ 250 nm.
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between the tested media 0.1 M HCl vs. PBS pH 3.0 
(f2 = 47.75). Despite the difference of drug dissolution 
found in 0.1 M HCl, 0.01 M HCl and PBS pH 3.0 media, 
the cumulative amount (94.44%, 89.07% and 84.33%, 
respectively) was greater than 80% in all media in the 
time point 15 min.
Figure 2b depicts the EC-MPS tablets dissolution 
profile. The first stage release was performed during 
120 min in 0.1 M HCl with the aim to evaluate the 
resistance of the enteric coating. In the second stage, the 
aim was to characterize the delayed release profile during 
120 min in the media PBS pH 5.5, 6.0 and 6.8. The tablets 
remained visually intact in the acid stage and the amount 
of drug released was negligible (0.0%). Moreover, there 
was a greater drug release with the increase of pH. The 
dissolution steady state was first achieved within 60 min in 
PBS pH 6.8. EC-MPS dissolution profile was significantly 
different in the media at all sampling times (p<0.05). 
Duncan test showed that the amounts of MPS dissolved in 
PBS pH 6.8 were significantly different when compared to 
those in PBS pH 5.5. The drug dissolution profile in PBS 
pH 6.0 was similar to that in PBS pH 5.5 at the two initial 
points and closer to that in PBS pH 6.8 at the final three 
dissolution points (Table III).
By using the similarity factor approach over the 
first 45 min for the second stage of the dissolution profile 
of EC-MPS tablets, f2 values were smaller than 50 and 
pointed for no similarity observed between the curves 
(f2 = 21.71 for pH 6.8 vs. 6.0; f2 = 13.93 for pH 6.8 vs. 5.5; 
f2 = 36.87 for pH 6.0 vs. 5.5). Hence, the pH was critical 
for the drug dissolution profile at this stage.
Dissolution kinetics
Dissolution kinetics was studied considered the 
dissolution profiles of MMF-IR and EC-MPS in 0.1 M 
HCl and PBS pH 6.8, respectively. The mathematical 
models for zero order, first order, Higuchi, Hixon-
Crowel and Weibull were applied to determine the best 
model to represent the dissolution process. Results of R2 
(coefficient of determination), intercept (β0) and slope (β1), 
normality test for standardized residual and significance 
of parameters were evaluated for MMF-IR and EC-MPS, 
according to Tables IV and V.
Method validation
Interference of placebo was not observed over the 
range 200-400 nm, attesting for the method selectivity. 
The calibration curves showed linearity over the ranges 
5.0-50.0 μg/mL for MMF and 6.0-34.0 μg/mL for MPA 
determinations. The regressions were significant (p<0.05) 
and data showed good curve fits. All R2 values were greater 
than 99.9%, which is the proportion explained by the 
TABLE II - Duncan test (α=0.05) for MMF-IR dissolution profiles in the media 0.1 M HCl, 0.01 M HCl and PBS pH 3.0 using UV 
method, λ 250 nm
Dissolution media
Time (min)
5 10 15 30 45 60
0.1 M HCl vs. PBS pH 3.0 15.45 10.52 10.11 6.01 5.95 7.24
0.1 M HCl vs. 0.01 M HCl 14.63 7.12 5.37 1.26* 1.10* 1.23*
0.01 M HCl vs. PBS pH 3.0 0.82* 3.40* 4.74 4.75 4.85 6.01
Critical value 7.56 3.91 3.53 3.75 2.37 2.73
*No significant difference.
TABLE III - Duncan test (α=0.05) for EC-MPS dissolution profiles in media PBS pH 5.5, 6.0 and 6.8, using UV method, λ 250 nm
Dissolution media
Time (min)
10 20 30 45 60 90 120
PBS pH 6.8 vs. PBS pH 5.5 1.19 29.83 57.32 83.08 67.55 17.58 7.03
PBS pH 6.8 vs. PBS pH 6.0 1.01 28.32 48.35 47.68 17.79* 0.44* 0.95*
PBS pH 6.0 vs. PBS pH 5.5 0.18* 1.51* 8.97 35.40 49.76 17.14 7.98
Critical value 0.37 6.30 8.67 11.16 18.84 10.20 1.83
*No significant difference.
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total variance of the response by the regression models 
(Table VI). The LOD and LOQ limits were calculated 
from the response standard deviation of the intercept and 
the slope of the analytic regression line. Estimated LOD 
value for MMF was 0.32 µg/mL and 0.13 µg/mL for MPA. 
The estimated LOQ values were 0.97 µg/mL for MMF and 
0.45 µg/mL for MPA.
The Table VII shows the precision and accuracy 
results. Precision was calculated by MMF and MPA 
determinations in tablets in three days. All RSD values were 
lower than 2.0% and there was no significant difference 
between averages in the three-day analyses (p>0.05). 
Accuracy, investigated by standard recovery over three 
different concentrations, resulted in experimental values 
near the nominal concentrations. Recovery means were 
99.28% for MMF and 99.84% for EC-MPS.
DISCUSSION
The dissolution media used was defined based 
on the best solubility and characteristics of the drug 
formulations. MMF is formulated as immediate release 
tablets, nevertheless, the drug is poorly soluble in water. 
Hence, an increase in hydrogen ion concentration of the 
TABLE IV - Results of the regression fit models for MMF-IR dissolution profile in selected medium 0.1 M HCl, using UV method, 
λ 250 nm
Model R2 (%)
β0 β1 Tests for normality of 
residuals (p-value)Estimated value p-value Estimated value p-value
Zero order 56.2 85.322 < 0.001 0.406 < 0.001 0.452
First order 54.5 4.446 < 0.001 0.005 < 0.001 0.331
Higuchi 64.2 78.780 < 0.001 3.427 < 0.001 0.460
Hixson-Crowell 55.1 0.239 < 0.001 − 0.007 < 0.001 0.369
Weibull 74.7 0.059 0.201 0.321 < 0.001 0.418
TABLE V - Results of the regression fit models for EC-MPS dissolution profile in selected medium PBS pH 6.8, using UV method, 
λ 250 nm
Model R2 (%)
β0 β1 Tests for normality of 
residuals (p-value)Estimated value p-value Estimated value p-value
Zero order 97.0 −23.163 < 0.001 2.654 < 0.001 0.016
First order 76.2 0.405 0.278 0.104 < 0.001 < 0.005
Higuchi 96.7 −83.813 < 0.001 26.302 < 0.001 0.120
Hixson-Crowell 87.0 3.835 0.001 − 0.091 < 0.001 0.018
Weibull 95.8 −5.118 < 0.001 3.457 < 0.001 0.059
TABLE VI - Results of linearity, LOD and LOQ for MMF and MPA in selected media 0.1 M HCl and PBS pH 6.8, respectively, 
using UV method, λ 250 nm
Coefficients MMF in 0.1 M HCl MPA in PBS pH 6.8
R2 (%) 99.98 99.99
Slope ± standard deviation 0.0203 ± 0.0001 0.0292 ± 0.0001
Intercept ± standard deviation 0.0030 ± 0.0020 0.0003 ± 0.0013
LOD (µg/mL) 0.32 0.13
LOQ (µg/mL) 0.97 0.45
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TABLE VII - Precision (n=18) and recovery (n=12) data for MMF-IR and EC-MPS tablets, in selected media 0.1 M HCl and PBS 
pH 6.8, respectively, using UV method, λ 250 nm
Precision for MMF-IR Precision for EC-MPS
Day Mean (%) RSD (%) Day Mean (%) RSD (%)
1 99.11 0.33 1 99.78 0.66
2 99.88 0.90 2 99.94 1.30
3 99.25 0.89 3 100.36 0.61
Recovery for MMF-IR Recovery for EC-MPS
Standard added 
(µg/mL)
Mean (%) RSD (%) Standard added 
(µg/mL)
Mean (%) RSD (%)
17.5 99.83 0.37 12.6 100.79 0.39
25.0 99.03 0.13 18.0 99.30 0.99
32.5 98.97 0.34 23.4 99.42 0.17
medium favors its solubility (Lee et al., 1990). Because 
of this feature, the acidic dissolution media 0.1 M HCl, 
0.01 M HCl and 0.1 M PBS pH 3.0 were selected to 
determine the dissolution profile of MMF tablets.
The mean release at 15 min in 0.1 M HCl was 
almost complete (94.44%) for MMF-IR. According to 
the regulatory agency Food and Drug Administration 
(USA, 1997), a drug product undergoing 85% dissolution 
in 15 min under mild dissolution test conditions behaves 
like a solution. Thus, generally, it should not have any 
bioavailability problems since the mean gastric emptying 
time (t50%) is 15 to 20 min under fasting conditions. The use 
of 0.1 M HCl as the dissolution medium was appropriate 
for MMF-IR and the acceptance criteria, Q=85%, for a 
very fast dissolving release (94.44%, in 15 min) can be 
applied as a quality control.
For EC-MPS, no drug release was detected at the acid 
stage. The MPS mean dissolution at 45 min of the buffered 
stage was 95.01% in pH 6.8, 47.33% in pH 6.0 and 11.93% 
in pH 5.5. The USP general method acceptance criteria 
for enteric-coated tablets consider the limit of 10% of the 
amount of drug dissolved in each unit after 120 min in 0.1 
M HCl. A minimum of 80% of the dissolved amount for 
each unit after 45 min of dissolution is recommended at 
the buffered stage. These criteria are suitable for analysis of 
EC-MPS dissolution evaluation in PBS pH 6.8.
A regression model is well adjusted when the 
average of the response variable Y is a linear function of 
the predictor variable X, the variance of the residuals is 
constant, the residuals follow the normal distribution with 
zero mean and are independent. The value of R2 represents 
the proportion of the total variability of the variable Y that 
is explained by the variable X. This index is widely used to 
classify a set of regression because it scales the ability of 
the predictor variable in determining the response variable. 
However, R2 should not be used as an isolated parameter 
without the validation of the assumptions established for 
the residuals in order to fit the regression model.
The zero order model was not ideal for evaluating 
the kinetics release of the drugs. The model did not show 
good ability to explain the data variation for MMF-IR 
(R2 = 56.2%). The R2 value was larger for EC-MPS 
(97.0%) but the residuals were not random and did not 
follow the normal distribution (p<0.05). The first order 
model had no advantage over the initial results compared 
to the zero order model.
Weibull transformation resulted in a significant 
(p<0.001) and valid regression for MMF-IR dissolution 
profile (Figure 3a). This model explained 74.7% of total 
variance of observations. The final regression model could 
be described by the Equation 6, where m is the cumulative 
fraction of drug dissolved over a time t.
For EC-MPS study, Higuchi transformation resulted 
in residuals with best fit to normal distribution. Noteworthy, 
β0 parameter was not significantly different from zero 
(p>0.05) only in first order model. This result is ideal 
because the drug release at time zero is null. Despite the 
merits of first order and Higuchi models, the best fit was yet 
obtained with Weibull transformation. The residuals showed 
to be random with constant variance (Levene test p=0.700) 
only with Weibull model. Data transformation resulted in a 
significant regression (p<0.001) and the model was able to 
explain 95.8% of the total data variation (Figure 3b). The 
regression could be described by Equation 7.
log (−ln(1−m)) = 0.05912 + 0.3210 log t   Eq. 6
log (−ln (1−m)) = − 5.118 + 3.457 log t   Eq. 7
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CONCLUSIONS
The results  obtained for  determination of 
mycophenolic acid derivatives after tablets dissolution 
by using UV spectrophotometry at λ 250 nm showed 
to be selective, linear, precise and accurate. The use of 
0.1 M HCl as a dissolution medium for MMF-IR was 
appropriate, considering dissolution acceptance criteria 
Q=85% of the labeled amount in 15 min. A minimum 
criterion of 80% of the dissolved amount after 45 min is 
proposed for EC-MPS in PBS pH 6.8.
Weibull model showed a significant (p<0.001) 
and best fit to linear regression for dissolution profile of 
MMF-IR and EC-MPS tablets. The obtained residuals 
were random, uncorrelated, and normally distributed with 
constant variance. The R2 values (74.7% for MMF-IR and 
95.8% for EC-MPS) demonstrated good ability of the 
Weibull regression to explain the variability and to predict 
the drug release from the reference dosage forms.
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